Rentschler Biopharma will buy Shire’s development and manufacturing facility in Milton, Massachusetts, where the latter makes haemophilia A product, Obizur, for commercial production.
Xenetic Biosciences says success for Shire’s haemophilia A candidate SHP656 will validate its PolyXen drug delivery technology platform and could net the firm up to $100m.
The acquisition of Shire for £31bn ($53bn) has moved a step closer but reliance on third party suppliers would only add two facilities to AbbVie's biomanufacturing network.
UK-based drugmaker Shire has unveiled plans to buy Advanced BioHealing (ABH) citing the lack of generic competition in the regenerative medicines sector as a factor.